ENERGIZE
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
- NCT03661320 ↗
- Completed
- Bristol-Myers Squibb
- Deep
We haven't built an HCP commentary report on ENERGIZE (nivolumab, gemcitabine and 1 more in Urinary Bladder Neoplasms) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ENERGIZE so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 79 | |
| YouTube | 16 | |
| Podcasts | 13 | |
| X videos | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy Alone Versus Neoadjuvant Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle- Invasive Bladder Cancer
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Urinary Bladder Neoplasms; Muscle-Invasive Bladder Cancer
- Interventions
- Nivolumab; Gemcitabine; Cisplatin
- Arms
- Arm A: Gemcitabine/Cisplatin (GC) Chemotherapy · Active comparator
- Arm B: Nivolumab + GC Chemotherapy · Experimental
- Enrollment
- 855
- Primary outcomes
- Pathological Complete Response (pCR) rate, in all randomized participants
- Event-Free Survival (EFS), in all randomized participants
- Sponsor
- Bristol-Myers Squibb with Ono Pharmaceutical Co., Ltd.
- Start
- Nov 6, 2018
- Primary completion
- Feb 16, 2026
- Results posted
- No
- Registry record
- NCT03661320 · updated Sep 10, 2026
Publications
linked from the registry- Grivas P, Koshkin VS, Chu X, Cole S, Jain RK, Dreicer R, Cetnar JP, Sundi D, Gartrell BA, Galsky MD, Woo B, Li-Ning-Tapia E, Hahn NM, Carducci MA. PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy. Eur Urol Oncol. 2024 Aug;7(4):914-922. doi: 10.1016/j.euo.2023.11.022. Epub 2023 Dec 27. PubMed 38155060
- Sonpavde G, Necchi A, Gupta S, Steinberg GD, Gschwend JE, Van Der Heijden MS, Garzon N, Ibrahim M, Raybold B, Liaw D, Rutstein M, Galsky MD. ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer. Future Oncol. 2020 Jan;16(2):4359-4368. doi: 10.2217/fon-2019-0611. Epub 2019 Dec 11. PubMed 31823654